Beta Bionics, Inc. is facing a securities class action lawsuit after the FDA issued a Warning Letter concerning its insulin pump's quality and complaint handling. Despite initial positive analyst coverage downplaying the FDA's concerns as procedural, the full letter revealed serious safety risks, leading to a 72% stock price decline from $31.99 to under $9 between January and April 2026. The lawsuit alleges the company misled investors by minimizing over 18,000 unreported complaints and mischaracterizing FDA findings. Investors who bought shares between July 2025 and February 2026 may be eligible to recover losses, with a lead plaintiff deadline set for November 3, 2026.
UBS increased its price target for ABM Industries to $51.50 following the company's strong quarterly earnings and revenue growth. ABM reported a 4.2% revenue increase to $2.32 billion and a 19% rise in net income to $49.7 million, alongside strong ca...
Chewy reported quarterly earnings of $0.36 per share, doubling analyst estimates of $0.18, with net income rising to $80.5 million from $62 million a year ago. Quarterly revenue reached $3.33 billion, slightly above expectations, marking a 7.3% incre...
AeroVironment, a leading drone maker, is set to report its Q3 earnings on September 9, 2026, with analysts expecting EPS between $0.22 and $0.25 and revenue near $452-$456 million. The company recently secured major contracts worth over $865 million ...
Bernstein has reduced the price target for Newmont Corporation to $144, reflecting challenges including a 13% drop in gold production and rising costs expected to reach $1,680 per ounce in 2026. Despite these issues, Newmont's stock gained 34.5% in A...
Barrick Mining maintains an 'Outperform' rating from Bernstein despite a lowered price target of $56.50, down from $61.00. The company reported an 11% increase in gold production in Q2 to 796,000 ounces, with further growth expected in the coming qua...
